Regado Biosciences, Inc., a Basking Ridge, NJ-based company focusing on a new therapeutic technology applied to injectable antithrombotics, announced the completion of a $40m Series D financing.
The round was led by new investor, Edmond de Rothschild Investment Partners, part of The LCF Rothschild Group, with participation from existing investors Domain Associates, Quaker Bioventures, Aurora Funds, Caxton Advantage Life Sciences Fund and other individual investors.
Proceeds from the financing will be used to continue the development of the company’s pipeline of programs in arterial and venous thrombosis, as well as the identification of a clinical candidate therapeutic aptamers.
FinSMEs
17/12/2009